engleski

PAI-1 and fibrinogen polymorphisms in patients with myocardial infarction in Croatia

Objective: To examine the association between polymorphisms of PAI-1 and fibrinogen genes and myocardial infarction in the case-control study. The PAI-1 -675 4G/5G promoter polymorphism and the beta-fibrinogen promoter -455 G/A polymorphism are associated with increased PAI-1 and fibrinogen plasma levels and could be potential risk factors for myocardial infarction. Patients and methods: 139 patients with myocardial infarction and 158 control group subjects. PCR-SSCP (PAI-1 polymorphism) and PCR-RFLP (fibrinogen polymorphism) genotyping. Results: Genotype distributions for PAI-1 polymorphism were 26.6% (37), 47.5% (66), 25.9% (36) in patient group vs. 29.1% (46), 45.6% (72), 25.3% (40) in control group for 4G4G, 4G5G, 5G5G, respectively. Allele frequencies were 50.4% and 49.6% in patient group vs. 51.9% and 48.1% in control group for 5G and 4G, respectively. Genotype distributions for fibrinogen polymorphism were 58.2%(64), 39.1%(43), 2.7%(3) in patient group vs. 54.3% (88), 40.7% (66), 4.3% (8) in control group for GG, GA, AA, respectively. Allele frequencies were 77.7% and 22.3% in patient group vs. 74.7% and 25.3% in control group for G and A, respectively. Tested genotypes were in Hardy-Weinberg equilibrium for both polymorphisms. No significant difference was observed for genotype and allele distributions between patient and control group (χ ; ; 2 test). Conclusion: Results suggest that PAI-1 and fibrinogen polymorphisms are not risk factors for myocardial infarction in our population.

PAI-1; fibrinogen polymorphisms; myocardial infarction

nije evidentirano